Atlas Trials

A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma

Clinical trial NCT06438614 · COMPLETED

Trial details

NCT number
NCT06438614
Sponsor
Fundació Sant Joan de Déu
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Refractory NeuroblastomaSoft Tissue Cancer
Start date
2020-08-20
Primary completion
2023-07-20
Enrollment
47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.